Brief: Dr Reddy's Clarifies News Report Dr. Reddy's Laboratories Still Awaiting Approval For A Major Near-Term Trigger
24/04/2026 06:36
April 24 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS: DR REDDY'S - CLARIFIES NEWS REPORT DR. REDDY'S LABORATORIES STILL AWAITING APPROVAL FOR A MAJOR NEAR-TERM TRIGGER DR REDDY'S - CO HAS NOT YET RECEIVED HEALTH CANADA APPROVAL FOR SEMAGLUTIDE INJECTION Source text: ID:nBSE3ytXyj Further company coverage: REDY.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption